Systematic review / meta-analysis / 2023
Berberine reduced LDL cholesterol, total cholesterol, triglycerides, and apolipoprotein B in adults with dyslipidemia, with sex-specific effects on HDL.
A systematic review and meta-analysis of 18 randomized placebo-controlled trials (n = 1,788, treatment durations 4 to 24 weeks) evaluated the efficacy and safety of berberine for dyslipidemia. Berberine significantly reduced LDL cholesterol (-0.46 mmol/L), total cholesterol (-0.48 mmol/L), triglycerides (-0.34 mmol/L), and apolipoprotein B (-0.25 g/L), while increasing HDL cholesterol overall (0.06 mmol/L). The effect on HDL cholesterol differed by sex, showing an increase in women (0.11 mmol/L) but not in men (-0.07 mmol/L). No serious adverse events were reported, though gastrointestinal adverse events were more frequent with berberine (2-23%) than placebo (2-15%).
- Study type
- Systematic review and meta-analysis of RCTs
- Who was studied
- 1,788 adult participants across 18 randomized placebo-controlled trials
- What was measured
- LDL cholesterol, total cholesterol, triglycerides, HDL cholesterol, apolipoprotein B, and adverse events
THE PAPER
Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
Blais JE, Huang X, Zhao JV. Drugs, 2023.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.